Which senolytic compounds achieve therapeutic CNS concentrations while maintaining selectivity for senescent cells?

OPEN

The debate noted BBB penetration challenges but didn't resolve which senolytics reach effective brain levels without off-target toxicity. This pharmacokinetic gap is essential for translating peripheral senolytic success to neurodegeneration. Source: Debate session sess_SDA-2026-04-04-gap-senescent-clearance-neuro_20260416-151700 (Analysis: SDA-2026-04-04-gap-senescent-clearance-neuro)

Priority: 0.82 Domain: pharmacology Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Which senolytic compounds achieve therapeutic CNS concentrations while maintaining selectivity for senescent cells? is a 0.82 priority gap in pharmacology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Which senolytic compounds achieve therapeutic CNS concentrations while maintaining selectivity for senescent cells? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (3)

ACY-738→CNSvenglustat→CNStherapeutic agents→CNS

describes (1)

cell-types-nodes-ranvier-neurod→CNS

expressed in (3)

BDNF→CNSMICROGLIA→CNSDAM→CNS

infects (1)

JEV→CNS

inhibits (1)

Eliglustat→CNS

is expressed outside (1)

38898538→CNS

is the primary lipid carrier within (1)

29563219→CNS

mediates (1)

BI-hTFR1→CNS

penetrate (1)

39009412→CNS

regulates (2)

MS→CNSperipheral immune system→CNS
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps